In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tengion completes its IPO

Executive Summary

Four months after filing, Tengion Inc. (regenerative medicine) has netted $28mm through its initial public offering of 6mm common shares at $5 each. The company had originally hoped to bring in $46mm, but then lowered its expectations to $41mm. Just last month it said it would sell 4.44mm shares for up to $10 apiece.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Implantable Devices
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies